Who Paid My Doc
Alvin Smith
Podiatrist Kansas City, MO Doctor of Podiatric Medicine
NPI 1336177534 CMS profile 543465
2713 East 31St Street, Kansas City, MO 64128
General payments
$27
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Alvin Smith of Kansas City, MO is reported in the CMS Open Payments database as having received $27 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 5th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $27 | 1 |
Beside peers
- Alvin Smith
- Podiatrist median
- Middle half of Podiatrist
- National median
In program year 2025, general payments to Alvin Smith were reported at $0. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.
Show as a table
| Year | Alvin Smith | Podiatrist median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $196 | $72–$601 | $163 |
| 2020 | $0 | $118 | $38–$335 | $114 |
| 2021 | $0 | $169 | $57–$573 | $132 |
| 2022 | $27 | $220 | $74–$782 | $149 |
| 2023 | $0 | $208 | $71–$635 | $160 |
| 2024 | $0 | $237 | $87–$681 | $164 |
| 2025 | $0 | $260 | $94–$777 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
327
Drug cost
$4,203
Branded share of claims
12.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Mupirocin Mupirocin Calcium | Brand | 11 | $802 | |
| Diclofenac Sodium | Generic | 72 | $735 | |
| Ciclopirox Ciclopirox Olamine | Brand | 31 | $579 | |
| Terbinafine Hcl | Generic | 56 | $470 | |
| Ammonium Lactate | Generic | 13 | $351 | |
| Clindamycin Phosphate | Generic | 14 | $309 | |
| Pregabalin | Generic | 31 | $298 | |
| Cephalexin | Generic | 15 | $197 | |
| Gabapentin | Generic | 36 | $186 | |
| Methylprednisolone | Generic | 12 | $115 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 10 billing codesPaid by Medicare
$22,168
Medicare patients
168
Services billed
548
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 55% | |
| Arthritis | 49% | |
| Chronic kidney disease | 35% | |
| Depression | 22% | |
| Heart failure | 20% | |
| Ischemic heart disease | 20% | |
| Cancer | 17% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Podiatrist in Missouri
Related records
Podiatrist in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Podiatrist
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.